These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 86447)

  • 1. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.
    Pannuti F; Martoni A; Di Marco AR; Piana E; Saccani F; Becchi G; Mattioli G; Barbanti F; Marra GA; Persiani W; Cacciari L; Spagnolo F; Palenzona D; Rocchetta G
    Eur J Cancer (1965); 1979 Apr; 15(4):593-601. PubMed ID: 86447
    [No Abstract]   [Full Text] [Related]  

  • 2. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
    Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
    Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of the treatment of patients with advanced breast with large doses of medroxyprogesterone acetate].
    Zulichowska J; Krawczyk J; Glińska H
    Pol Tyg Lek; 1988 May; 43(22):712-4. PubMed ID: 2976163
    [No Abstract]   [Full Text] [Related]  

  • 4. Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial.
    Elomaa I; Blomqvist C; Rissanen P; Mäntylä M
    Acta Oncol; 1988; 27(3):297-9. PubMed ID: 2970862
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages.
    De Lena M; Villa S; Di Fronzo G
    Recent Results Cancer Res; 1984; 91():243-7. PubMed ID: 6203147
    [No Abstract]   [Full Text] [Related]  

  • 6. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 10. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the results of treatment with medroxyprogesterone acetate (MPA) of patients with advanced breast cancer].
    Pieńkowska F; Siedlecki P; Pieńkowski T; Zborzil J; Rubach M
    Nowotwory; 1985; 35(3):243-8. PubMed ID: 2935789
    [No Abstract]   [Full Text] [Related]  

  • 13. High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.
    Mattsson W
    Acta Radiol Oncol Radiat Phys Biol; 1978; 17(5):387-400. PubMed ID: 162770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].
    Amadori D; Ravaioli A; Barbanti F
    Minerva Med; 1977 Dec; 68(59):3967-80. PubMed ID: 74811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
    Jakobsen A; Frederiksen PL; Møller KA; Andersen AP; Brincker H; Dombernowsky P; Hansen PV; Hesselius I; Kjaer M
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1067-72. PubMed ID: 2946583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)].
    Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt J; Rose C
    Ugeskr Laeger; 1979 Jul; 141(31):2113-6. PubMed ID: 483409
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC
    Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.